Peter L.J. de Keizer
Erasmus University Medical Center
Biography & Research Background
Peter L.J. de Keizer, PhD, is the primary inventor of FOXO4-DRI and founder of Cleara Biotech B.V. in Utrecht, Netherlands. He held research positions at Erasmus University Medical Center Rotterdam (Department of Molecular Genetics), University Medical Center Utrecht (Center for Molecular Medicine), and The Buck Institute for Research on Aging. De Keizer conceptualized and designed the FOXO4-DRI peptide after identifying FOXO4 as the critical pivot maintaining senescent cell viability through p53 sequestration. His landmark 2017 paper in Cell demonstrated that disrupting the FOXO4-p53 interaction could selectively eliminate senescent cells, restoring tissue homeostasis in aging and chemotherapy models. He founded Cleara Biotech to translate these findings into clinical therapies, developing 4th-generation optimized variants (CL04183). His key publications include "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging" (2017, Cell) and "The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI" (2025, Nature Communications). Peter L.J. de Keizer is being referenced as one of the leading scientists involved in FOXO4-DRI research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Peter L.J. de Keizer is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Peter L.J. de Keizer is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.